Establishment and Preclinical Therapy of Patient-derived Hepatocellular Carcinoma Xenograft Model.

[1]  Meijuan Huang,et al.  Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma , 2019, Hepatology.

[2]  R. Sun,et al.  Tissue-resident lymphocytes: from adaptive to innate immunity , 2019, Cellular & Molecular Immunology.

[3]  A. Ashkar,et al.  Shining light on the significance of NK cell CD56 brightness , 2018, Cellular & Molecular Immunology.

[4]  M. Shiao,et al.  Sorafenib suppresses TGF‐&bgr; responses by inducing caveolae/lipid raft‐mediated internalization/degradation of cell‐surface type II TGF‐&bgr; receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma , 2018, Biochemical pharmacology.

[5]  B. Kwon.  IFN-γ in tissue-immune homeostasis and antitumor immunity , 2018, Cellular & Molecular Immunology.

[6]  H. Kumar,et al.  Balancing anti-viral innate immunity and immune homeostasis , 2018, Cellular & Molecular Immunology.

[7]  W. Zou.  Mechanistic insights into cancer immunity and immunotherapy , 2018, Cellular & Molecular Immunology.

[8]  P. Hsu,et al.  Tumor necrosis factor: The key to hepatitis B viral clearance , 2018, Cellular & Molecular Immunology.

[9]  M. A. Khan,et al.  Clinical epidemiology and disease burden of nonalcoholic fatty liver disease , 2017, World journal of gastroenterology.

[10]  Rohit Loomba,et al.  Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity , 2017, Nature.

[11]  Anang A. Shelat,et al.  Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors , 2017, Nature.

[12]  Suna Wang,et al.  Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma , 2017, Front. Immunol..

[13]  Meijuan Huang,et al.  High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer , 2017, Oncoimmunology.

[14]  J. Lahuerta,et al.  Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma , 2016, Oncoimmunology.

[15]  S. Cairo,et al.  Patient‐derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management , 2016, Hepatology.

[16]  G. Wang,et al.  Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: From patients to patient-derived tumor xenograft models , 2016, Oncotarget.

[17]  S. Cheung,et al.  Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line , 2016, Cancer Cell International.

[18]  A. Barbieri,et al.  Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX , 2016, BioMed research international.

[19]  Mengchao Wu,et al.  An Artificially Designed Interfering lncRNA Expressed by Oncolytic Adenovirus Competitively Consumes OncomiRs to Exert Antitumor Efficacy in Hepatocellular Carcinoma , 2016, Molecular Cancer Therapeutics.

[20]  W. Wels,et al.  NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy , 2016, Cancer Immunology, Immunotherapy.

[21]  R. Sun,et al.  Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6* , 2015, The Journal of Biological Chemistry.

[22]  Y. Naito,et al.  Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer , 2015, Journal of Translational Medicine.

[23]  Mingjin Yang,et al.  An In Vivo Method to Identify microRNA Targets Not Predicted by Computation Algorithms: p21 Targeting by miR-92a in Cancer. , 2015, Cancer research.

[24]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[25]  Z. Tian,et al.  NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma , 2014, Cellular and Molecular Immunology.

[26]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[27]  Danyi Wen,et al.  Establishment and Characterization of 7 Novel Hepatocellular Carcinoma Cell Lines from Patient-Derived Tumor Xenografts , 2014, PloS one.

[28]  E. Seifried,et al.  Treatment of patients with advanced cancer with the natural killer cell line NK-92. , 2013, Cytotherapy.

[29]  Z. Tian,et al.  NK cells in immunotolerant organs , 2013, Cellular and Molecular Immunology.

[30]  Jinjun Li,et al.  Establishment of NOD/SCID mouse models of human hepatocellular carcinoma via subcutaneous transplantation of histologically intact tumor tissue. , 2013, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[31]  H. El‐Serag,et al.  Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.

[32]  Wen Jiang,et al.  Natural killer cell lines in tumor immunotherapy , 2012, Frontiers of Medicine.

[33]  Binqing Fu,et al.  TGF-β1 Down-Regulation of NKG2D/DAP10 and 2B4/SAP Expression on Human NK Cells Contributes to HBV Persistence , 2012, PLoS pathogens.

[34]  Wan-Hsin Liu,et al.  Role of microRNAs in hepatitis B virus replication and pathogenesis. , 2011, Biochimica et biophysica acta.

[35]  I. Ng,et al.  Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma , 2011, Gut.

[36]  K. Jin,et al.  Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review , 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[37]  C. Pui,et al.  NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  F. Heindryckx,et al.  Experimental mouse models for hepatocellular carcinoma research , 2009, International journal of experimental pathology.

[39]  E. Alici,et al.  Natural killer cell‐based immunotherapy in cancer: current insights and future prospects , 2009, Journal of internal medicine.

[40]  H. Ljunggren,et al.  NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy , 2008, Cancer Immunology, Immunotherapy.

[41]  S. Fan,et al.  Significance of CD90+ cancer stem cells in human liver cancer. , 2008, Cancer cell.

[42]  H. Ljunggren,et al.  Prospects for the use of NK cells in immunotherapy of human cancer , 2007, Nature Reviews Immunology.

[43]  H. Huynh,et al.  Xenografts of Human Hepatocellular Carcinoma: A Useful Model for Testing Drugs , 2006, Clinical Cancer Research.

[44]  S. Lam,et al.  Establishment in Severe Combined Immunodeficiency Mice of Subrenal Capsule Xenografts and Transplantable Tumor Lines from a Variety of Primary Human Lung Cancers: Potential Models for Studying Tumor Progression–Related Changes , 2006, Clinical Cancer Research.

[45]  E. Sausville,et al.  Contributions of human tumor xenografts to anticancer drug development. , 2006, Cancer research.

[46]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[47]  L. Kèlland,et al.  Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. , 2004, European journal of cancer.

[48]  Mark J. Smyth,et al.  Functional significance of the perforin/granzyme cell death pathway , 2002, Nature Reviews Immunology.

[49]  P. Johnson,et al.  Systemic therapy for hepatocellular carcinoma. , 2001, Seminars in oncology.

[50]  M. Christian,et al.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.

[51]  V. Ho,et al.  Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. , 1999, Journal of hematotherapy.

[52]  Xin-da Zhou,et al.  Cryotherapy for primary liver cancer. , 1998, Seminars in surgical oncology.